Pharvaris NV（PHVS）の株式分析PHVSPharvaris NV

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet. It operates in the Healthcare sector.

Pharvaris NV (PHVS) is a good buy right now due to its recent clinical trial success, which has driven analyst price targets significantly higher, with the average target around $54. Additionally, the stock is currently priced at $27.74, which is well below the lowest analyst target of $40, suggesting substantial upside potential. However, the main risk is the company's ongoing net losses, which amounted to €47.8 million in the last quarter, indicating financial instability that could affect future performance.